JoinHealth Spring welcome Webinars 2026

Opening  

Health Cluster Portugal
EIT Health Innostars

PT2030 – Framework and Context

• What PT2030 is and how it works.
• Different programs and instruments available to companies.

The “Big 4” of PT2030

• Overview of the four core support typologies.
• How they align with the business life cycle.

Funding Instruments Overview

• R&D (Research & Development).
• Productive Innovation.
• SME Qualification.
• SME Internationalization.

Complementary Tax Incentives

• Key tax incentives that can complement PT2030 funding.
• Important rules and constraints on accumulation.

Key Takeaways & Next Steps

• How to identify the right instrument for your company.
• Practical guidance on preparation and timing.

Speaker: Ana Henriques (Senior Project Manager, IPN)

Q&A Session

Closing remarks

Health Cluster Portugal
EIT Health Innostars

Opening  

Health Cluster Portugal
EIT Health Innostars

Industrial Property applied to the digital health fields

• Industrial Property: key concepts.
• Patentability requirements.
• Patents in Digital Health: key considerations and pitfalls.
   

Intellectual Property Strategies for Digital Health Startups and SMEs

• The relevance of intellectual property for attracting investment, partnerships, and scale-up.
• Industrial property according to the solution’s development stage: relevance and strategic approaches.
• Opportunities and challenges.

Speaker: Alexandra Mendes (Patent Examiner, INPI) 

Case study: How Industrial Property can contribute to a company’s success – the Perceive3D case

Q&A Session

Closing remarks

Health Cluster Portugal
EIT Health Innostars

Opening

Health Cluster Portugal
EIT Health Innostars

Preclinical evidence behind the guidelines

• What Preclinical Evidence Is Expected - and at What Stage.
• Linking Preclinical Evidence to the General Safety and Performance Requirements (GSPR).
• Usability Studies as Part of Preclinical Evidence.

Speaker: Ana Brito (Coordinator of the Medical Devices Regulatory Support Unit, IPN)

Clinical Evaluation Strategy

• Building a Risk‑Aligned Clinical Evaluation Strategy.
• The Art of Literature: Building a Robust Clinical Evaluation Report (CER).
• Integrating PMS, PMCF and Evidence Generation in a Clinical Evidence Lifecycle.

Speaker: Inês Urbano (Medical Devices Regulatory Affairs Consultant, IPN)

Early clinical validation

• The Sweet Spot: When Early Validation Drives Real Progress.
• ISO 14155 fundamentals for early feasibility and pilot studies.
• Designing high‑quality early clinical studies: Endpoints, Methodology & Scalable Evidence.

Speaker: Maria Nascimento (Testing and Validation Sub-Unit Coordinator, IPN)

Q&A Session

Closing  

Health Cluster Portugal
EIT Health Innostars